Register

Endometrial Cancer   

Questions discussed in this category

Would development of a rectovaginal fistula mid-treatment with second line pembrolizumab/lenvatinib for endometrial cancer cause you to change regimens, eliminate lenvatinib, or continue current therapy?
The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...
1 Answer available
How would you treat a recurrent endometrial cancer at the vaginal cuff that was initially FIGO 1A with no adj treatment, in a patient with actively treated scleroderma?
3 Answers available
Would you include a seroma in an adjuvant radiation field for post-op endometrial cancer?
Is there any particular reason to include or not include this in the treatment volumes?
3 Answers available
Do you routinely check tumor genomics, including POLE status for new endometrial cancers?
How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling?
1 Answer available
What is your approach to an incidental diagnosis of low risk endometrial cancer in a patient who underwent minimally invasive hysterectomy with uterine morcellation with gross intra-operative tumor spillage?
1 Answer available
In which circumstances would you offer adjuvant brachytherapy to a surgically staged patient with endometrial cancer if they have received prior pelvic external beam radiation therapy for a non-gynecologic pelvic tumor?
1 Answer available
If a patient with HER2+ uterine serous carcinoma recurs while on maintenance trastuzumab, would you continue trastuzumab with second line chemotherapy?
Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.
2 Answers available
What is the optimal interval between vaginal cuff brachytherapy sessions?
At our institution we often give 5.5 Gy x 4 fractions. There really does not appear to be a general consensus regarding timing. Interested in what oth...
5 Answers available
Is adjuvant treatment recommend for a 0.8cm serous endometrial CA confined to polyp s/p hysterectomy + surgical staging?
2 Answers available
In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?
Do you stop therapy at 2 years or continue until progression of disease?
1 Answer available
What are your top takeaways from SGO 2022?
10 Answers available
How would you counsel a patient with incidental diagnosis of at least high intermediate risk endometrial cancer, found on robotic hysterectomy with non-contained uterine morcellation and no node sampling?
Path significant for LVSI and MELF pattern. Post-operative CT negative for metastatic disease. 
1 Answer available
Do you modify your treatment for a patient with ulcerative colitis needing vaginal brachytherapy?
2 Answers available
Would you offer adjuvant RT to a FIGO IV endometrial CA with pulm mets s/p hysterectomy with residual disease, then cCR to both sites after chemotherapy?
1 Answer available
How do you manage a cT3bN0 endometrial cancer with large vaginal drop met s/p NAC and TAH/BSO with pCR?
Would you recommend whole pelvis as well as vaginal cuff brachytherapy?
1 Answer available
What is your adjuvant therapy for node positive, low grade endometrioid endometrial adenocarcinoma?
3 Answers available
How do you manage early stage I uterine serous carcinoma?
VC brachy, pelvic RT, +/- chemo?  Does your management change if it is confined to the endometrium without myometrium invasion or if it is only ...
3 Answers available
How do you treat a Stage II Grade 3 endometrioid endometrial adenocarcinoma?
1 Answer available
Do you treat an endometrial cancer that is microsatellite-stable but has a high TMB after progressing on platinum-based therapy with pembrolizumab?
2 Answers available
Would you offer adjuvant radiation in addition to chemotherapy for a patient with stage IIIC uterine carcinosarcoma with cervical involvement?
2 Answers available
Do you give vaginal cuff brachytherapy or whole pelvis (or both), for patients with Stage III endometrial adenocarcinoma?
5 Answers available
How do you approach a patient with recurrent endometrial cancer within the field of prior primary radiation who is not a surgical or cytotoxic chemotherapy candidate?
1 Answer available
What is the best method for ensuring that vaginal cuff cylinder is in proper position at each fraction?
3 Answers available
In patients diagnosed with endometrial cancer who do not undergo SLNB or LND at the time of hysterectomy, what criteria is used to recommend completion surgery for LN assessment?
2 Answers available
What is your preferred surgical management of an endometrial cancer with clinically apparent extension to the cervix?
No parametrial involvement on MRI.
2 Answers available
Would you recommend adjuvant therapy for a non-invasive Grade 3 endometrioid endometrial cancer that is P53 wild-type and MMR deficient (due to methylation)?
1 Answer available
What is the longest acceptable interval between hysterectomy and vaginal cuff brachytherapy for high/intermediate risk endometrial cancer in the age of COVID-19?
2 Answers available
When do you include the presacral nodes in post-operative XRT of endometrial cancer?
Would involvement of the PA nodes be an indication?
1 Answer available
With vaginal cuff brachytherapy, do you treat to the surface or a depth and why?
1 Answer available
What is optimal therapy for a 5 year delayed recurrence of uterine cancer, rendered NED by solitary pulmonary metastasis resection?
And if the tumor is MSI-H, does that alter your thoughts?
3 Answers available
How would you proceed with the management of a healthy patient with stage IV grade 3 endometrioid uterine cancer metastatic to the right diaphragm and other peritoneal surfaces?
No mesenteric/small bowel/lesser sac involvement on imaging
1 Answer available
How do you approach a medically inoperable patient with clinically stage 2 grade 1 endometrioid endometrial carcinoma with heavy vaginal bleeding that is refractory to EBRT and requiring inpatient management with transfusions?
1 Answer available
What HDR dosing would you use in the neoadjuvant setting of endometrial cancer?
1 Answer available
How would you treat a patient with pT1bN0 G1 endometrioid carcinoma with significant MMI (~80%) and +LVSI?
EBRT vs VB? She technically meets PORTEC2, but also meets GOG99 and GOG249 (for pelvic RT) and PORTEC4. NCCN recommends for IB grade 1 vaginal brachyt...
2 Answers available
What are indications to add WPRT +/- PA field to chemotherapy for uterine serous carcinoma?
2 Answers available
Is there a role for elective para-aortic nodal irradiation in endometrial cancer?
Is there any indication for ENI in early stage disease or in advanced stages, without pathologic confirmation or PET positivity or CT size criteria?
1 Answer available
Would you consider maintenance therapy in a recurrent endometrial cancer that is MSI-H and ER/PR+ that achieved a complete response after pelvic RTx and 4 cycles of Carbo/Taxol?
1 Answer available
How would you manage an elderly but otherwise healthy patient with a high grade endometrioid uterine cancer with micro metastasis to a SLN, but otherwise confined to the uterus with superficial myometrial invasion?
2 Answers available
How would you approach second isolated vaginal cuff recurrence in a young patient with FIGO IA Grade 2 endometrioid endometrial adenocarcinoma who received EBRT+ interstitial brachy for her initial recurrence?
The patient was initially observed after radical hysterectomy due to young age, FIGO IA grade 2 disease. The patient had isolated, biopsy-proven vagi...
3 Answers available
Would you offer consolidative radiation for oligometastatic uterine serous CA s/p surgery and chemotherapy with complete response?
1 Answer available
How do you plan for excess nonconforming vaginal tissue with a HDR cylinder?
In women receiving HDR intracavitary brachytherapy to treat the vaginal cuff, how do you overcome the challenge of excess lateral vaginal tissue ("dog...
3 Answers available
Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?
1 Answer available
Do you routinely perform bilateral oophorectomy at the time of hysterectomy for a premenopausal woman with a uterine leiomyosarcoma that appears to be limited to the uterus?
Does ER/PR status help guide your decision?
1 Answer available
Would you give adjuvant therapy after diagnosis of presumed stage IA, 5cm, ER/PR+ uterine adenosarcoma on a total hysterectomy with bilateral salpingoopheretomy without staging?
No sarcomatous overgrowth seen.
1 Answer available
How would you approach adjuvant therapy for a IIIC2, FIGO grade 2, endometrial cancer with 1/7 positive (para-aortic) lymph nodes?
PET- CT before surgery visualised a tumor localised to the uterus and a PET positive 3 cm enlarged node at L3 level.  Final path: endometroid FI...
1 Answer available
How would you deliver/time radiation for a patient with IIIC1 serous endometrial cancer who is HER2+?
Planning carboplatin/taxol/trastuzumab. Cervical stromal invasion on path. Looking for pelvic vs brachy and timing with chemotherapy.
1 Answer available
What is your approach to the management of early-stage mixed-histology endometrial cancer with a significant clear-cell component?
How do you take into account pathologic factors like %clear cell histology, myometrial invasion, and LVSI?  
2 Answers available
How would your follow-up change for a patient, non-surgical candidate, with endometrial cancer treated with definitive radiation?
2 Answers available
Do you recommend sentinel lymph node dissection or full lymphadenectomy for high grade and type II uterine cancers?
1 Answer available
What normal tissue constraints do you use, if any, in patients receiving vaginal cuff brachytherapy alone?
2 Answers available
What adjuvant therapy do you recommend for comprehensively staged, Stage II, FIGO grade 3 deeply invasive endometrial cancer?
1 Answer available
How would you treat a stage IA mixed carcinosarcoma/neuroendocrine tumor of the endometrium, negative LNs?
6.6cm tumor, 15% MI
1 Answer available
How would you manage a clinically inoperable, stage IIIB, MMR deficient uterine cancer?
Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement. ER/PR and HER2 testing are pending.
1 Answer available
Would uterine serosal involvement change your adjuvant treatment recommendation for a patient with Stage II grade 2 endometrial cancer?
Tumor traverses the myometrium to focally involve the serosa; 1/6 sentinels with ITC and the rest negative. 
2 Answers available
If a patient with recurrent endometrial cancer experiences minimal or slow disease progression on pembrolizumab or pembro/lenvatinib, would you consider continuing or would you change agents?
Patient has tolerated combination therapy well to date.
1 Answer available
How does number of ITC influence your approach to adjuvant RT for a surgically staged 1B endometrial cancer meeting HIR criteria?
Pt is 73yo, Grade 1, 81% invasion, MELF like features, foci of LVSI, and 47 ITCs identified.
3 Answers available
Do you recommend adjuvant therapy for early stage (IB) high grade endometrial stromal sarcoma?
1 Answer available
How would you sequence chemotherapy and radiotherapy for a patient with stage IIIC1 serous endometrial carcinoma?
HER2 status is pending
2 Answers available
Would you change your approach to adjuvant radiation for an incompletely staged, at least IB, grade 1 endometrial cancer, if a uterine perforation occurred at time of surgery?
Pt is 69yo, tumor 1.4cm, negative LVSI, ER/PR +
5 Answers available
How does positive p53 staining influence your recommendation for adjuvant therapy in comprehensively staged early (stage IA or IB), grade 2, endometrioid endometrial cancers? 
If patient meets high intermediate risk criteria, would you consider chemotherapy in addition to radiation?
1 Answer available
Would the presence of multifocal LVSI change your adjuvant treatment recommendation for a surgically staged IA dedifferentiated endometrial carcinoma?
Does not technically meet high intermediate risk criteria.
2 Answers available
Outside of a clinical trial, do you currently incorporate the TCGA molecular classification into management decisions for patients with endometrial cancer?
2 Answers available
How do you counsel patients regarding adjuvant therapy for stage IA uterine serous carcinoma confined to a polyp?
2 Answers available
How would you deliver pelvic radiation as cost-efficiently as possible for a patient with endometrial cancer?
In the unfortunate setting where you cannot get an underinsured patient whose policy does not cover radiotherapy started on treatment without guarante...
2 Answers available
How would the presence of micro-metastatic disease in multiple sentinel pelvic lymph nodes change your recommendation for adjuvant therapy in a patient with otherwise stage I endometrioid adenocarcinoma?
1 Answer available
For a recurrent, MSI-H endometrial cancer, do you usually treat with Pembrolizumab alone or in combination with Lenvatinib?
1 Answer available
How would you manage a recurrent uterine leiomyosarcoma, now status post secondary cytoreduction, with no gross residual disease?
Would you consider adjuvant chemotherapy, radiation therapy, hormone therapy, or surveillance?
1 Answer available
How do you manage early stage uterine carcinosarcoma?
Do you give cuff and chemo or pelvic CRT or chemo alone?
3 Answers available
How do you sequence chemotherapy with radiotherapy for advanced endometrial cancer?
4 Answers available
What is your treatment approach to a young woman with widely metastatic low grade endometrial stromal aarcoma not amenable to complete cytoreduction?
Would you consider "neoadjuvant" hormonal therapy to shrink tumors and potentially make more amenable to complete cytoreduction at a later date? Woul...
1 Answer available
Would you consider staging lymph node dissection for a patient referred for stage IA endometrial cancer and MELF pattern on final pathology?
Incidental diagnosis after hysterectomy
2 Answers available
Would you recommend adjuvant therapy for a 1A grade 2 endometrial adenocarcinoma with MELF pattern, and ITCs in one pelvic lymph node?
1 Answer available
How does sarcomatous overgrowth in a uterine carcinosarcoma change your management of adjuvant therapies?
1 Answer available
What adjuvant therapy would you offer a patient with Stage II uterine serous carcinoma without lymph node sampling?
3 Answers available
How would you manage recurrent endometrial cancer limited to pelvic and inguinal nodes in a patient with no previous radiation?
1 Answer available
How would you manage a Stage IB endometrioid endometrial cancer, status post staging surgery, with a rapid vaginal recurrence <1 month post operatively?
This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...
2 Answers available
When would you add a vaginal cuff brachy boost to external beam radiation for uterine carcinosarcoma?
Would you offer EBRT alone or EBRT with vaginal cuff brachytherapy after surgery and chemotherapy for stage III (T3N0) carcinosarcoma of the uterus? ...
1 Answer available
How do you counsel patients with BRCA-1 mutations regarding the role of hysterectomy as a part of risk-reducing surgery?
2 Answers available
Would you offer adjuvant therapy following successful resection of a solitary lung recurrence of leiomyosarcoma if no other evidence of recurrent disease on PET CT?
1 Answer available
What starting dose of lenvatinib are you ultilizing in recurrent endometrial cancer patients initiating lenvatinib/pembro?
1 Answer available
Would you recommend systemic therapy in a patient with a history of Stage III high grade serous endometrial cancer s/p resection of a solitary pulmonary metastasis after a long disease free interval?
Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?
2 Answers available
What, if any, treatment do you offer a a patient with Stage I Endometrial Clear Cell Carcinoma?
1 Answer available
Which tumor markers, if any, would you use to follow patients with high grade or advanced endometrial cancers?
2 Answers available
Would you offer adjuvant progesterone therapy to a young woman with low grade endometrial stromal sarcoma who had elected ovarian conservation?
1 Answer available
Do you recommend concurrent chemotherapy with XRT for inoperable patients with stage I-II high-risk endometrial carcinoma?
Ie for patients who are inoperable due to comorbidities?
2 Answers available
Do you offer pelvic radiation for endometrial cancer with ITCs in the node(s) and no other high or intermediate risk factors?
1 Answer available
What adjuvant therapy would you offer a fully resected isolated pelvic peritoneal recurrence of a uterine serous carcinoma?
1 Answer available
What dose is needed for salvage RT for recurrent endometrial cancer in untreated PA region (who has received pelvic RT) after good PET response to systemic therapy?
For a patient with good response to immunotherapy (unable to receive chemotherapy due to kidney function, comorbidities) where previously avid LN have...
1 Answer available
What adjuvant treatment would you offer a young woman with stage IB uterine mullerian adenosarcoma with sarcomatous overgrowth?
1 Answer available
Is there any benefit to giving pelvic radiation prior to systemic chemotherapy or vice versa for a patient with stage IIIA uterine serous carcinoma?
HER2 positive
1 Answer available
Would you recommend maintenance therapy with a PARP inhibitor for BRCA+ patients with advanced uterine serous cancer?
Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...
1 Answer available
Do PORTEC-3 and GOG-258 change your approach to managing patients with high-risk or node positive endometrial cancer?
http://abstracts.asco.org/199/AbstView_199_180760.html http://abstracts.asco.org/199/AbstView_199_187537.html  
3 Answers available
Would you consider pembrolizumab plus lenvatinib for stage IV uterine carcinosarcoma after progression on chemotherapy as per Keynote-146?
1 Answer available
Do you offer vaginal cuff brachy alone, vaginal cuff brachy and chemo, or WPRT for surgically staged IB grade 3 endometrial cancer?
Does the GOG 249 abstract guide you one way or the other?
3 Answers available
For a patient with recurrent endometrial cancer involving the vagina with a good response to EBRT (<5mm residual), how would you prescribe adjuvant brachytherapy with a cylinder to the entire vaginal length?
2 Answers available
How successful is IVF after definitive radiation therapy to the pelvis for endometrial cancer?
How do you counsel a pre-menopausal female with endometrioid cancer desiring definitive RT with egg harvesting and IVF for fertility preservation inst...
2 Answers available
Would you offer adjuvant chemotherapy in addition to pelvic RT in a patient with fully resected pelvic recurrence of endometrial carcinoma?
1 Answer available
What chemotherapy options are there for clear cell carcinoma of uterus with progression of disease on carboplatin and paclitaxel?
1 Answer available
With COVID-19 worries, are you more likely to offer women with endometrial cancer vaginal cuff brachytherapy over EBRT?
1 Answer available
In a patient metastatic recurrent endometrioid endometrial cancer who has a mixed response to carboplatin and paclitaxel, what is your next choice of therapy?
 No adjuvant treatment was given upfront
1 Answer available
What is your process for obtaining and using next generation sequencing on patients with advanced endometrial cancer?
1 Answer available
In a patient with a vaginal cuff recurrence from endometrial cancer not amenable to interstitial brachytherapy, how would you boost after 45Gy?
Insurance authorization for protons is pending, but if the patient cannot have protons would you treat with standard fractionation to ~70Gy or conside...
1 Answer available
In a surgically staged Stage II Grade 1 endometrial adenocarcinoma, with no other high risk factors, would you treat with brachytherapy alone or add on the pelvic RT?
NCCN recommends brachytherapy plus or minus pelvic RT for surgically staged Grade 1, Stage II patients, but these originally staged IIB patients were ...
4 Answers available
Would you recommend radiotherapy for a para-aortic recurrence of endometrial cancer in a patient who previous completed surgery, chemotherapy, and WPRT?
1 Answer available
Would you recommend radiation for micrometastasis on sentinel lymph node biopsy in otherwise low risk endometrial cancer?
1 Answer available
How does the presence of microcystic elongated and fragmented (MELF) invasion impact post operative treatment of Stage IA FIGO grade 1 endometrial cancer?
1 Answer available
How would you approach an inoperable, elderly, frail patient with high risk endometrial cancer?
1 Answer available
How would you treat an endometrial cancer with pelvic sidewall nodes, patient s/p TAH/BSO but nodes were fixed and unresectable?
Would you consider EBRT or brachytherapy boost to the nodes? what dose would you recommend?
2 Answers available
When do you use a vaginal cuff boost with pelvic RT for stage II endometrial cancer?
For the management of stage II endometrial cancer, NCCN says pelvic RT and/or vaginal brachytherapy.   Do you ever add vaginal cuff boost to pelv...
3 Answers available
Would you offer adjuvant radiation to a patient with uterine undifferentiated sarcoma s/p resection, vaginal cuff recurrence, and re-resection?
If so, would you treat the whole pelvis, cuff brachytherapy, or both?
2 Answers available
Does the presence of a POLE mutation in endometrial cancer guide your recommendations regarding adjuvant radiation?
1 Answer available
How would you approach a young patient with a locally advanced endometrial cancer with cervical involvement and a solitary bone metastasis?
2 Answers available
What alternative boost methods (techniques / dose) do you recommend for a vaginal cuff boost after whole pelvis when imaging shows bowel adherent to the vaginal cuff?
1 Answer available
Would the findings of a synchronous T1a ovarian endometrioid adenocarcinoma affect your treatment recommendation for a IB, G2 uterine endometrioid adenocarcinoma and LVSI?
2 Answers available
How do you treat a Stage I endometrial squamous cell carcinoma?
MRI and cervical biopsy are negative for cervical involvement 
1 Answer available
Would focal clear cell features change your management for a grade 2 endometrial adenocarcinoma?
1 Answer available
For a patient with vaginal adhesions/stenosis, do you recommend any other therapy besides a dilator?
Would estrogen cream be helpful in this scenario?
1 Answer available
Do you continue Megestrol in a patient with inoperable endometrial cancer during definitive radiation therapy?
are there any positive or negative synergies from combined megestrol/RT treatment?
1 Answer available
Would uterine perforation at the time of hysterectomy push you to recommend pelvic RT in a patient who would otherwise receive cuff brachytherapy?
1 Answer available
Is obesity a risk factor for recurrence after definitive treatment for endometrial cancer?
At what point would you introduce the discussion of weight management, whether for risk reduction or overall health?
1 Answer available
How do you decide on adjuvant therapy in a patient with a Stage IA uterine carcinosarcoma without any myometrial invasion?
The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...
1 Answer available
How would you treat a patient with a FIGO G1 pT1bN0 endometrial adenoCA involving the lower uterine segment with >50% invasion and a separate focus of disease found involving the endocervical mucosa with no cervical stromal invasion?
The disease involving the endocervix was felt to be separate and appeared like a drop metastases
1 Answer available
Are you using the new FIGO 2018 staging or waiting until it is incorporated into the next AJCC edition?
4 Answers available
Do you recommend stopping olaratumab in patients receiving doxorubicin/olaratumab for treatment of advanced sarcoma?
Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...
1 Answer available
For a patient with carcinosarcoma of the uterus and an allergic reaction to paclitaxel, would you have any reservations about using docetaxel instead?
1 Answer available
What is the maximum time you would wait after hysterectomy to start RT for a FIGO II endometriod adenocarcinoma before cancelling treatment and saving for salvage?
1 Answer available
How do you treat endometrial cancer in the setting of a pCR after neoadjuvant chemotherapy?
Female in her 60s who had presented originally with well-differentiated endometrioid adeno clinically and radiographically involving bilateral paramet...
1 Answer available
How do you approach adjuvant therapy of serous intraepithelial carcinoma of the endometrium?
For a woman with complete resection of serous intraepithelial carcinoma of the endometrium, would you recommend adjuvant radiation or chemotherapy? Wh...
1 Answer available
What factors do you use to determine whether to add brachytherapy to EBRT for IIIC endometrial cancer?
Current NCCN guidelines suggest that vaginal brachytherapy is optional, and there may be concern for over-treatment locally given competing risk of di...
3 Answers available
Do you have any normal tissue constraints for endometrial cancer patients receiving EBRT and vaginal cuff brachytherapy?
1 Answer available
Do you add chemotherapy to pelvic radiation and brachytherapy for an isolated vaginal cuff recurrence of endometrial cancer?
3 Answers available
Are there any situations in which you would offer brachytherapy alone instead of whole pelvis RT +/- brachytherapy for an endometrial cancer vaginal cuff recurrence?
2 Answers available
When do you offer observation for resected stage II endometrial cancer?
In what situations is it appropriate to offer observation (rather than VBT) to patients with stage II endometrial carcinoma who have had a radical hys...
1 Answer available
How would you manage a patient with low-volume non-invasive endometrioid carcinoma that is found in both the endometrium and ovary (pN0)?
Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...
2 Answers available
How would you approach the management of a patient with locally advanced cervical cancer as well as synchronous endometrial adenocarcinoma?
1 Answer available
What strategies have you found to be most helpful in improving patient compliance with vaginal dilator use after pelvic radiotherapy?
1 Answer available
How does positive peritoneal washings factor into your treatment decisions regarding pelvic radiation and/or chemotherapy?
For example, in an otherwise intermediate risk localized endometrial cancer (Grade 2, FIGO IB)?
1 Answer available
How do you decide whether to treat proximal vs. entire vaginal cuff with intracavitary brachytherapy in early-stage endometrial adenocarcinoma?
What clinicopathologic features do you typically consider?
2 Answers available
What clinical and pathological factors guide your decision making when considering whether to recommend vaginal cuff brachytherapy following TAH/BSO for a FIGO stage IA or IB endometrial carcinoma?
2 Answers available
Would you include a lymphocele in your IMRT treatment volumes for endometrial carcinoma?
If the post-operative simulation films reveal a significant lymphocele secondary to pelvic lymph node sampling, is it imperative that the entire lymph...
1 Answer available
For which patients with stage IA nonsurgically staged endometriod cancer would you add pelvic RT?
The gyn oncs at my institution sometimes will not perform lymphadenectomy if biopsy indicates low risk disease. Would LVSI as sole adverse risk factor...
1 Answer available
What is the optimal management of a pelvic sidewall recurrence of endometrial cancer in a patient who has not previously received radiation?
2 Answers available
What is your technique to calculate the vaginal surface dose in gyn intracavitary brachytherapy?
What exactly do you contour and what is your dose constraint to that volume?
4 Answers available
What is the role of parametrial and pelvic side wall boosts in the setting of volumetric brachytherapy for locally advanced cervical cancer treated with either 3DCRT or IMRT?
Does using something like a vienna applicator allow you to avoid dose escalation with more external beam? How do you recommend doing a classic pa...
2 Answers available
What are you posterior field borders for endometrial and cervical cancer 3DCRT plans?
Some classic references recommend the coverage of the entirety of the sacrum but the volume delineation guidelines for both seem to only cover the mos...
1 Answer available
Do the number of lymph nodes removed in a non-Stage IA/FIGO 1 endometrial cancer case, affect your decision for WPRT v. vaginal brachytherapy alone?
1 Answer available
Once endometrial cancer recurs after no chemo or XRT, is it curative or palliative?
Does hydroureter and leg edema alter your opinion?
1 Answer available
What is the best treatment for a medically inoperable endometrial adenocarcinoma of the uterus FIGO 1, grade 1, type 1?
Brachytherapy, EBRT or both and what is the best dose?
1 Answer available
What lessons can we learn from RTOG 0418 in how to best use IMRT to treat endometrial cancer?
1 Answer available


Papers discussed in this category

Gynecologic oncology, 2004-03
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
The New England journal of medicine, 2019-06-13
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2005-08-01
Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels.
Int. J. Radiat. Oncol. Biol. Phys., 1990-02-01
Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I.
Gynecologic oncology, 2003-12
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
Int. J. Radiat. Oncol. Biol. Phys., 2014-05-01
Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.
Brachytherapy, 2015
Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer.
Gynecologic oncology, 2007-11
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Eur. J. Cancer, 2008 Apr 02
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
J Clin Oncol,
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
Gynecologic oncology, 2018-10
Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
Gynecologic oncology, 2014-11
Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
Lancet, 2010-03-06
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
International journal of radiation oncology, biology, physics, 2018-08-01
Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.
Brachytherapy, 2019 Sep - Oct
Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion.
Gynecologic oncology, 2009-10
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-01-01
Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology, 2013-10
Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.
Gynecologic oncology, 2013-01
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.
Eur. J. Cancer, 2010 Jul 07
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Lancet Oncol., 2019 Jul 22
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Gynecol Oncol, 2019 Sep
Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Cancer Nurs, 2017-04-21
Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study.
American journal of clinical oncology, 2018-08
Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study.
Cancer, 1987-10-15
Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.
Gynecologic oncology, 2015-09
Ovarian involvement in endometrioid adenocarcinoma of uterus.
Brachytherapy, 2016 Nov - Dec
Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-10
Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
Practical radiation oncology, 2017
Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.
Gynecologic oncology, 2018-08
Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.
International journal of radiation oncology, biology, physics, 2017-04-01
Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Gynecol Oncol, 2017 Aug
Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
J Gynecol Oncol, 2015 Nov 23
Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer.
Int J Gynaecol Obstet,
Postirradiation vaginal occlusion: nonoperative management.
Int J Womens Health, 2017 May 02
Radiation-induced vaginal stenosis: current perspectives.
Radiat Oncol, 2015 Feb 22
Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation.
Obstet Gynecol,
Treatment of clear cell adenocarcinoma in young females.
Annals of surgical oncology, 2016-05
Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma.
Gynecologic oncology, 2003-07
Low-grade endometrial stromal sarcoma: hormonal aspects.
Obstetrics and gynecology, 2013-09
Endometrial stromal sarcoma: a systematic review.
Lancet Oncol.,
Clinical management of uterine sarcomas.
Gynecol. Oncol., 2005 Dec 20
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Int J Gynecol Cancer,
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
International journal of radiation oncology, biology, physics, 2014-03-15
Interval between hysterectomy and start of radiation treatment is predictive of recurrence in patients with endometrial carcinoma.
Brachytherapy, 2015
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer.
Nature, 2013-05-02
Integrated genomic characterization of endometrial carcinoma.
Gynecologic oncology, 2019-09
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
F1000Res, 2019 Jun 12
Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.
Lancet Oncol., 2018 Feb 12
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Lancet, 2019 Apr 11
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Gynecologic oncology, 2001-10
Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Int. J. Gynecol. Pathol.,
Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases.
Gynecol. Oncol., 2019 Sep 26
Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.
Gynecologic oncology, 2017-08
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
Am J Obstet Gynecol, 2016 Nov 18
Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis.
Eur J Cancer, 2019 Jun 07
Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.
J Clin Med, 2020 Nov 28
Diagnostic Accuracy and Clinical Impact of Sentinel Lymph Node Sampling in Endometrial Cancer at High Risk of Recurrence: A Meta-Analysis.
Int J Gynecol Cancer, 2019 Dec 18
Robotic sentinel lymph node (SLN) mapping in endometrial cancer: SLN symmetry and implications of mapping failure.
Gynecol Oncol, 2019 Jul 22
Lymph node micrometastases and outcome of endometrial cancer.
JAMA oncology, 2016-11-01
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Gynecologic oncology, 2013-04
Management of uterine adenosarcomas with and without sarcomatous overgrowth.
Lancet, 2008 Dec 16
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
J. Natl. Cancer Inst., 2008 Nov 25
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Gynecologic oncology, 2019-04
Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.
J Gynecol Oncol,
Evaluation of the optimal sequence of adjuvant chemotherapy and radiation therapy in the treatment of advanced endometrial cancer.
Gynecol Oncol, 2020 Aug 15
Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
Gynecologic oncology, 2009-10
Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
Am J Obstet Gynecol, 2017 Dec 06
Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database.
Lancet,
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
Journal of minimally invasive gynecology, 2016-02-01
Timing of Intrauterine Manipulator Insertion During Minimally Invasive Surgical Staging and Results of Pelvic Cytology in Endometrial Cancer.
Am J Obstet Gynecol, 2020 Jul 18
Impact of uterine manipulator on oncological outcome in endometrial cancer surgery.
The Lancet. Oncology, 2017-03
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
International journal of radiation oncology, biology, physics, 2004-03-01
Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
Gynecologic oncology, 2015-11
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Gynecol Oncol, 2020 May 29
Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.
Cancer, 2017-03-01
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Lancet Oncol, 2019 Mar 25
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Gynecologic oncology, 2007-06
Outcomes in surgical stage I uterine papillary serous carcinoma.
Int J Gynecol Cancer,
Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
Gynecol Oncol Rep, 2020 Jan 30
Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literature.
World J Surg Oncol, 2017 Jan 10
Dedifferentiated endometrioid carcinoma of the uterus : report of four cases and review of literature.
Gynecologic oncology, 2012-10
High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes.
Practical radiation oncology, 2019
Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.
Brachytherapy, 2019 Apr 17
Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer-Does it predict treatment response?
Brachytherapy, 2019
Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report.
Radiother Oncol, 2020 Nov 05
Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.
Brachytherapy, 2021 Mar 26
Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit.
The American journal of surgical pathology, 2017-01
The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.
Histopathology, 2011 Mar 25
MELF invasion in endometrial cancer as a risk factor for lymph node metastasis.
J Minim Invasive Gynecol, 2021 Feb 08
Hysteroscopic Morcellation in Endometrial Cancer Diagnosis: Increased Risk?
Gynecologic oncology, 2019-06
Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
Gynecol Oncol, 2021 Mar 05
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Brachytherapy, 2020 Dec 29
Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?
Brachytherapy, 2002
Postoperative intravaginal brachytherapy for endometrial cancer; dosimetric analysis of vaginal colpostats and cylinder applicators.
Gynecologic oncology, 2019-04
Endocrine therapy in endometrial cancer: An old dog with new tricks.
Gynecol Oncol, 2017 Jul 06
Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
Cochrane Database Syst Rev, 2011 Jun 15
Adjuvant progestagens for endometrial cancer.
Gynecologic oncology, 2014-05
Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies.
International journal of radiation oncology, biology, physics, 2017-12-01
Reirradiation Using Permanent Interstitial Brachytherapy: A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies.
Gynecologic oncology, 2019-03
Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.
Int J Gynecol Cancer,
Low-volume lymphatic metastasis (isolated tumor cells) in endometrial cancer: management and prognosis.
The Lancet. Oncology, 2014-02
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-01
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2004
Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review.
Arch Gynecol Obstet, 2009 Mar 21
Splenic metastasis from endometrial carcinoma: report of a case and review of literature.
Strahlenther Onkol, 2011 Nov 17
Hematogenous metastases in patients with Stage I or II endometrial carcinoma.
Gynecol Oncol Res Pract, 2016 Jun 17
Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.
Brachytherapy, 2012
American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy.
The New England journal of medicine, 2018-11-15
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy.
Int J Gynecol Cancer, 2020 Aug 04
Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
J Clin Oncol, 2019 Nov 04
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol, 2020 Mar 13
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Int J Gynecol Cancer, 2020 Dec 18
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
N Engl J Med, 2022 Jan 19
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Gynecol Oncol, 2020 Nov 05
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
N Engl J Med, 2021 Sep 18
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
International journal of radiation oncology, biology, physics, 2013-01-01
The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Cancer, 2009-05-15
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
Gynecologic oncology, 2018-05
The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Virchows Arch,
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
JAMA, 2014-09-24
Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2008
Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.
Eur J Surg Oncol, 2012 Jun 14
Association of breast tumour bed seroma with post-operative complications and late normal tissue toxicity: results from the Cambridge Breast IMRT trial.
Arthritis care & research, 2018-10
Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.